Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

Journal of the American College of Cardiology

Volumn 71, Issue 16, 2018, Pages 1755-1764

  Mahmood, Syed S ^a,b   Fradley, Michael G ^c   Cohen, Justine V ^b   Nohria, Anju ^d   Reynolds, Kerry L ^b   Heinzerling, Lucie M ^e   Sullivan, Ryan J ^b   Damrongwatanasuk, Rongras ^c   Chen, Carol L ^f   Gupta, Dipti ^f   Kirchberger, Michael C ^e   Awadalla, Magid ^b   Hassan, Malek Z O ^b   Moslehi, Javid J ^g   Shah, Sachin P ^h   Ganatra, Sarju ^h   Thavendiranathan, Paaladinesh ⁱ   Lawrence, Donald P ^b   Groarke, John D ^d   Neilan, Tomas G ^b  

^a WEILL CORNELL MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h LAHEY HOSPITAL AND MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF TORONTO   (Canada)

Author keywords

cardio oncology; checkpoint inhibitor; ipilimumab; myocarditis; nivolumab; pembrolizumab

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DURVALUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNE CHECKPOINT INHIBITOR; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INFLIXIMAB; IPILIMUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; NIVOLUMAB; PEMBROLIZUMAB; STEROID; THYMOCYTE ANTIBODY; TICILIMUMAB; TROPONIN T; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COLITIS; COMPLETE HEART BLOCK; CONTROLLED STUDY; DERMATITIS; DIABETES MELLITUS; DISEASE REGISTRY; DRUG MEGADOSE; FEMALE; GASTRITIS; HEART ARREST; HEART EJECTION FRACTION; HEART HEMODYNAMICS; HEPATITIS; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSITIS; LOW DRUG DOSE; MAJOR ADVERSE CARDIAC EVENT; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYOCARDITIS; PNEUMONIA; PREVALENCE; PRIMARY TUMOR; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SIDE EFFECT;

EID: 85043452821     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2018.02.037     Document Type: Article

References (33)

1. Hodi, F.S., O'Day, S.J., McDermott, D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010 (2010), 711–723.
2. Robert, C., Thomas, L., Bondarenko, I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364 (2011), 2517–2526.
3. Approved Drugs - Nivolumab (Dec 22, 2014). Silver Spring, MD: U.S. Food and Drug Administration, 2014.
4. Approved Drugs - Pembrolizumab (Sep 4, 2014). Silver Spring, MD: U.S. Food and Drug Administration, 2014.
5. Johnson, D.B., Balko, J.M., Compton, M.L., et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 375 (2016), 1749–1755.
6. Tadokoro, T., Keshino, E., Makiyama, A., et al. Acute lymphocytic myocarditis with anti-PD-1 antibody nivolumab. Circ Heart Fail, 9, 2016, e003514.
7. Laubli, H., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., Zippelius, A., Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunother Cancer, 3, 2015, 11.
8. Heinzerling, L., Ott, P.A., Hodi, F.S., et al. Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy. J Immunother Cancer, 4, 2016, 50.
9. Zimmer, L., Goldinger, S.M., Hofmann, L., et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer 60 (2016), 210–225.
10. Andrews, A., Treating with checkpoint inhibitors—figure $1 million per patient. Am Health Drug Benefits, 8 Spec Issue, 2015, 9.
11. Webster, R.M., The immune checkpoint inhibitors: where are we now?. Nat Rev Drug Discov 13 (2014), 883–884.
12. Lexicomp, Drug Information Handbook: A Clinically Relevant Resource for All Healthcare Professionals. 26 edition, 2017, Wolters Kluwer, Indianapolis, IN.
13. Caforio, A.L., Pankuweit, S., Arbustini, E., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34 (2013), 2636–2648.
14. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. 2009, U.S. Department of Health and Human Services, Bethesda, MD.
15. Hicks, K.A., Tcheng, J.E., Bozkurt, B., et al. 2014 ACC/AHA key data elements and definitions for cardiovascular endpoint events in clinical trials: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol 66 (2015), 403–469 Erratum in: J Am Coll Cardiol 2015;66:982.
16. Neilan, T.G., Farhad, H., Mayrhofer, T., et al. Late gadolinium enhancement among survivors of sudden cardiac arrest. J Am Coll Cardiol Img 8 (2015), 414–423.
17. Reynolds, H.R., Hochman, J.S., Cardiogenic shock: current concepts and improving outcomes. Circulation 117 (2008), 686–697.
18. Epstein, A.E., DiMarco, J.P., Ellenbogen, K.A., et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 61 (2013), e6–e75.
19. Neilan, T.G., Shah, R.V., Abbasi, S.A., et al. The incidence, pattern, and prognostic value of left ventricular myocardial scar by late gadolinium enhancement in patients with atrial fibrillation. J Am Coll Cardiol 62 (2013), 2205–2214.
20. Wolchok, J.D., Chiarion-Sileni, V., Gonzalez, R., et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med 377 (2017), 1345–1356.
21. Kindermann, I., Kindermann, M., Kandolf, R., et al. Predictors of outcome in patients with suspected myocarditis. Circulation 118 (2008), 639–648.
22. Sznol, M., Ferrucci, P.F., Hogg, D., et al. Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma. J Clin Oncol 35:34 (2017), 3815–3822.
23. Armenian, S.H., Lacchetti, C., Barac, A., et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 35 (2016), 893–911.
24. Friedrich, M.G., Sechtem, U., Schulz-Menger, J., et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol 53 (2009), 1475–1487.
25. Naidoo, J., Wang, X., Woo, K.M., et al. Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy. J Clin Oncol 35 (2016), 709–717.
26. Bernardo, S.G., Moskalenko, M., Pan, M., et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res 23 (2013), 47–54.
27. Huffman, B.M., Kottschade, L.A., Kamath, P.S., Markovic, S.N., Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clinical Oncol, 2017 Jul 26 [E-pub ahead of print].
28. Hofmann, L., Forschner, A., Loquai, C., et al. Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60 (2016), 190–209.
29. Ammirati, E., Cipriani, M., Lilliu, M., et al. Survival and left ventricular function changes in fulminant versus nonfulminant acute myocarditis. Circulation 136 (2017), 529–545.
30. Gräni, C., Eichhorn, C., Bière, L., et al. Prognostic value of cardiac magnetic resonance tissue characterization in risk stratifying patients with suspected myocarditis. J Am Coll Cardiol 70 (2017), 1964–1976.
31. Ederhy, S., Voisin, A.L., Champiat, S., Myocarditis with immune checkpoint blockade. N Engl J Med 376 (2017), 290–291.
32. Haanen, J., Carbonnel, F., Robert, C., et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28 (2017), iv119–iv142.
33. Mehra, M.R., Canter, C.E., Hannan, M.M., et al. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: a 10-year update. J Heart Lung Transplant 35 (2016), 1–23.